NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
Neuropace, Inc. (NPCE)
Company Research
Source: Business Wire
-- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) ---- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission ---- Remains on track to submit NAUTILUS PMA Supplement to FDA for IGE indication expansion by year-end 2025 -- MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the American Epilepsy Society (AES) meeting of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS1 trial evaluating the RNS® System as an adjunctive therapy for the treatment of antiseizure medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic (GTC) seizures.At 18 months of therapy, patients treated with the RNS System experienced a 77% median reduction in GTC seizur
Show less
Read more
Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- NeuroPace (NASDAQ:NPCE) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- NeuroPace (NASDAQ:NPCE) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $20.00. They now have an "overweight" rating on the stock.MarketBeat
- NeuroPace (NASDAQ:NPCE) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual MeetingBusiness Wire
NPCE
Earnings
- 11/4/25 - Beat
NPCE
Sec Filings
- 12/4/25 - Form 4
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- NPCE's page on the SEC website